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(1)
DESCRIBED	ASRANDOMISED
1 1 1 1 1 1 1 1 1 1
(2)
DESCRIBED	ASDOUBLEBLIND
0 0 0 0 0 0 0 0 1 0
(3)
DESCRIPTION	OFWITHDRAWALS
1 1 1 1 0 1 1 1 1 1
(4)
RANDOMISATIONMETHODDESCRIBED
1 0 1 1 0 0 1 1 1 1
(5)
DOUBLEBLINDINGMETHODDESCRIBED
0 0 0 0 0 0 0 0 1 0
SCORE	(-/5) 3/5 2/5 3/5 3/5 1/5 2/5 3/5 3/5 5/5 3/5












STUDY SELECTION COMPARABILITYOU COME SCORE
	 A B C D E F G H 	
GRANT2002	(13)
(p)
* * * * ** * * * 9*
LODISE2007	(16)
(R)
* * * * ** * * * 9*
LORENTE2009	(18)
(R)
* * * * ** * * * 9*
ROSE2011	(35)
(R)
* * * * ** * * * 9*
YOST2011	(21)
(R)
* * * * * * * * 8*
PEREIRA2012	(23)
(R)
* * * * ** * * * 9*
LEE	2012
(24)	(R)
* * * * ** - * * 8*
WAXIER2012	(25)
(R)
* * * * ** - * * 8*
CUTRO2014	(27)
(R)
* * * * * * * * 8*
SCHMEES2016	(31)
(R)
* * * * ** - * * 8*
WINSTEAD	2016
(30)	(R)
* * * * ** - * * 8*
FAN	2017
(34)	(P)
* * * * ** - * * 8*
(P) = PROSPECTIVE	COHORT	STUDY	AND	(R) = RETROSPECTIVE	COHORT	STUDYSELECTION:
A:	REPRESENTATION	OF	THE	EXPOSED	COHORT	(YES	=	*)	(NO=	-),	B:	SELECTION	OF	NON-EXPOSED	COHORT	(YES
=	*)	(NO=	-),	C:	ASCERTAINMENT	OF	EXPOSURE	(YES	=	*)	(NO=	-),	D:	DEMONSTRATION	THAT	OUTCOME	OF
INTEREST	WAS	NOT	PRESENT	AT	START	OF	STUDY	(YES	=	*)	(NO=	-)
COMPARABILITY:
E:	COMPARABILITY	OF	COHORTS	ON	THE	BASIS	OF	THE	DESIGN	OR	ANALYSIS	[CONTROLS	FOR:	AGE,	SEX	AND
MARITAL	STATUS	(YES	=	*)	(NO=	-)	AND	FOR	OTHER	FACTORS	(YES	=	*)	(NO=	-)]
OUTCOME:
F:	ASSESSMENT	OF	OUTCOME	(YES	=	*)	(NO=	-),	G:	WAS	FOLLOW	UP	LONG	ENOUGH	FOR	OUTCOME	TO	OCCUR
(YES	=	*)	(NO=	-)	AND	H:	ADEQUACY	OF	FOLLOW	UP	OF	COHORTS	(YES	=	*)	(NO=	-).
Meta-Analysis	of	Included	Studies
Clinical	Cure
Seventeen	of	the	included	studies	reported	clinical	cure	rates	(Table	1)	(6,13,26–29,31–33,14,15,18–
21,23,24).	Patients	that	received	C/PI	had	a	statistically	significantly	higher	clinical	cure	rate
compared	to	those	who	received	treatment	via	II	(2535	patients;	OR	1.56,	95%	C.I	1.28–1.90,	P = 0
.0001;	Fig.	2).	No	significant	heterogeneity	was	found	among	the	studies	(I2 = 41%,	P = 0.04).	The
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symmetrical	funnel	plot	obtained	indicates	the	absence	of	publication	bias	(Fig.	3).
Despite	methodological	differences	among	selected	studies,	patients	receiving	C/PI	displayed	higher
clinical	cure	rates	compared	with	patients	receiving	II;	overall,	clinical	cure	rate	was	79.62%	and
69.26%	for	C/PI	and	II	respectively.	Pooling	results	from	the	17	studies	that	reported	clinical	cure
showed	that	the	odds	of	clinical	cure	was	higher	in	patients	receiving	C/PI.	The	pooled	OR	shows	that
C/PI	piperacillin-tazobactam	was	1.56	(95%	C.I	1.28–1.90,	P = 0	.0001),	indicating	clinical	cure	rates
are	34%	higher	than	in	II	with	the	true	population	effect	between	72%	and	10.
Mortality
Eighteen	of	the	included	studies	reported	patient	mortality	rates	(Table	1)	(13,14,28–34,36,15–
18,20,21,24,27).	Statistically	significantly	fewer	mortality	rates	were	found	among	patients	receiving
C/PI	compared	with	patients	receiving	conventional	II	(3100	patients;	OR	0.68,	95%	C.I	0.55–0.84,	P = 
0	.0003;	Fig.	4).	No	significant	heterogeneity	was	found	among	the	studies	(I2 = 0%,	P = 0.56).	The
symmetrical	funnel	plot	obtained	indicates	the	low	possibility	of	publication	bias	(Fig.	5).
Results	obtained	from	meta-analysis	suggested	that	C/PI	piperacillin-tazobactam	resulted	in
significantly	lower	mortality	rates.	Overall,	ICU	mortality	rate	was	12.46%	and	18.13%	for	C/PI	and	II
respectively.	Combining	results	from	18	studies	that	reported	mortality,	the	pooled	OR	shows	that
C/PI	piperacillin-tazobactam	was	0.68	(95%	C.I	0.55–0.84),	indicating	lower	mortality	rates	compared
with	conventional	II.	This	was	statistically	significant	(P = 0.0003)	with	the	true	population	effect
between	84%	and	55%.
Microbiological	Cure
Seven	of	the	included	studies	reported	microbiological	cure	rates	(13,14,19,20,23,27,33).	Lau	et	al
(14)	found	no	statistically	significant	difference	between	the	dosing	regimens	however,	higher
microbiological	success	was	seen	in	patients	receiving	II.	In	contrast,	Abdul-Aziz	et	al	(33)	found	C/PI
piperacillin-tazobactam	had	significantly	higher	microbiological	cure	rates	compared	with	II.	Pooling	of
the	outcomes	of	seven	studies	that	reported	microbiological	cure	rates	showed	that	patients	receiving
C/PI	had	significantly	higher	microbiological	success	rates	(920	patients;	OR	1.52,	95%	C.I	1.10–2.11,
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P = 0.01;	Fig.	6).	No	significant	heterogeneity	was	found	among	studies	(I2 = 0%,	P = 0.48).	The
symmetrical	funnel	plot	obtained	demonstrates	the	absence	of	publication	bias	(Fig.	7).
The	pooled	OR	shows	that	C/PI	piperacillin-tazobactam	was	1.52	(95%	C.I	1.10–2.11),	indicating	C/PI
piperacillin-tazobactam	achieved	higher	microbiological	cure	rates	compared	to	conventional	II.
Overall,	microbiological	cure	rates	were	74.83%	and	61.89%	for	C/PI	and	II	respectively.	This	was
statistically	significant	(P = 0.01).
Adverse	Events
Six	of	the	included	studies	reported	adverse	events	(13,14,31–34).	Participants	enrolled	in	three	of
these	studies	observed	adverse	event	(14,31,32).	The	average	occurrence	of	adverse	events	was
13.3%	for	C/PI	and	13.4%	for	II,	respectively.	Participants	in	the	other	three	studies	did	not	experience
adverse	events	(13,33,34).	Data	obtained	from	studies	showed	no	significant	difference	between	the
two	infusion	strategies	(935	patients;	OR	0.85,	95%	C.I	0.50–1.42,	P = 0.53;	Fig.	8).	No	significant
heterogeneity	was	found	among	studies	(I2 = 25%,	P = 0.26).
From	the	23	studies,	six	reported	data	regarding	adverse	events	that	occurred	during	the
administration	of	piperacillin-tazobactam	for	both	dosing	regimens.	Three	studies	reported	that
adverse	events	were	not	observed	(13,33,34)	however,	dosing	and	administrative	errors	arose	in	the
study	by	Grants	et	al	(13)	where	one	patient	was	administered	13.5	g	piperacillin-tazobactam	dose
over	a	30	minute	II	rather	than	a	24-hour	CI.	Lau	et	al’s	(14),	Bao	et	al	(32)	Schmees	et	al	(31)
observed	treatment-related	adverse	events	in	patients	receiving	both	C/PI	and	II;	CI:	16.9%	vs
II:13.6%,	CI:	47.5%	vs	II:53.8%,	CI:	76%	vs	II:92%,	respectively.
Boa	(32)	reported	seriously	adverse	events	in	9	patients	(PI:5	vs	II:4),	including	renal	failure,
Tachycardia	and	confusion.	Cortina	et	al	(29)	reported	that	the	most	common	side	effects
experienced	by	patients	were	gastrointestinal	and	allergic	reactions	but	the	number	of	patients	that
experienced	these	was	not	reported.	The	meta-analysis	demonstrated	that	no	adverse	events	that
are	directly	associated	to	the	dosing	regimens	occurred.	C/PI	resulted	in	a	lower	percentage	of
adverse	events	however,	the	difference	between	the	two	groups	did	not	reach	statistical	significance
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(935	patients;	OR	0.85,	95%	C.I	0.50–1.42,	P = 0.53;	Fig.	8).
Length	of	Hospital	Stay
Fifteen	of	the	included	studies	reported	length	of	hospital	stay	(13,14,31,33–
35,37,15,16,18,23,24,26,29,30).	Pooling	of	studies	showed	that	patients	receiving	C/PI	had	a
significantly	shorter	length	of	hospital	stay	(2101	patients;	OR	-1.27,	95%	C.I	-2.45—0.08,	P = 0.04;
Fig.	9)	The	meta-analysis	suggests	there	is	a	significant	reduction	in	the	length	of	hospital	stay	in
patients	receiving	C/PI	compared	to	those	receiving	II.	Moderate	heterogeneity	among	studies
evaluating	‘length	of	hospital	stay’	(I2 = 65%,	P = 0.0003)	was	observed.	This	is	likely	due	to	clinical
heterogeneity	in	the	design	and	outcomes	of	the	included	studies.
Emergence	of	Resistance
Data	regarding	the	emergence	of	resistance	was	reported	in	four	of	the	included	studies
(13,14,17,18).	Two	resistant	pathogens	were	isolated	in	one	study	(13)	however,	resistant	strains
were	not	isolated	in	three	studies	(14,17,18)	following	the	initiation	of	piperacillin-tazobactam
treatment.	Three	studies	reported	that	no	resistant	pathogen	was	isolated	following	the	initiation	of
piperacillin-tazobactam	treatment.	In	the	study	conducted	by	Grant	et	al	(13),	two	resistant	strains
were	isolated	from	patients	receiving	CI	piperacillin-tazobactam.
Risk	of	Bias
The	majority	of	RCT’s	and	prospective	studies	assessed	were	judged	to	have	a	low	risk	of	bias	for
random	sequence	generation,	allocation	concealment,	incomplete	outcome	data,	selective	reporting
and	other	biases.	However,	evaluations	of	blinding	of	participants	and	personnel	parameter	was
judged	to	have	a	high	or	unclear	risk	of	bias.
4	Discussion
To	the	best	of	our	knowledge,	this	systematic	review	and	meta-analysis	is	the	largest	study	describing	clinical
outcomes	of	severely	ill	patients	treated	with	either	C/PI	or	II	piperacillin-tazobactam.	The	selected	studies
involved	3828	critically	ill	adult	participants	in	total	(C/PI = 2197	and	II = 1631)	from	geographically	diverse
regions.
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It	is	the	first	meta-analysis	that	shows	C/PI	resulted	in	significantly:	(1)	higher	clinical	cure	rates	(2)	lower	of
mortality	rates	(3)	higher	microbiological	success	rates	and	(4)	decreasing	the	length	of	hospital	stay	specifically
in	critically	ill	patients.	In	all	the	studies,	the	primary	outcome	assessed	was	clinical	efficacy.	The	current	study
differs	from	previously	published	systematic	reviews	and	meta-analyses	(4,38–44)	as	it	specifically	focuses	on
use	of	piperacillin-tazobactam	in	critically	ill	ICU	patients.	The	present	systematic	review	and	meta-analysis
identified	a	significant	clinical	cure,	mortality,	microbiological	cure	and	length	of	hospital	stay	benefit	for	C/PI
across	all	included	studies.
In	theory,	C/PI	of	piperacillin-tazobactam	is	a	broadly	recognised	strategy	to	optimize	antibiotic	therapy,	where
concentrations	remain	above	the	MIC	for	a	higher	percentage	of	time.	Studies	have	demonstrated	that	the
amount	of	time	in	which	the	free	or	non-protein	bound	antibiotic	concentration	exceeds	the	MIC	(fT > MIC)	of	the
organism	is	the	best	predictor	of	clinical	and	microbiologic	response	for	β-lactams	(45,46).	However,	data	to
backup	this	developing	practice	have	been	sparse	(42).	Twenty-three	published	studies	comparing	C/PI	and	II	of
piperacillin-tazobactam	fit	the	inclusion	criteria	(Table.2).
Outcomes	of	the	current	study	correlate	and	expand	upon	previously	published	reviews	including	several
analyses	comparing	clinical	efficacy	of	dosing	regimens	for	beta-lactams	generally	(38–41).	These	studies	pointed
towards	a	more	favourable	outcome	of	C/PI	for	improved	clinical	cure	and	resolution	of	illness.	Falagas	et	al	2013
(39)	and	Vardakas	el	al	2018	(40)	reviewed	outcomes	of	C/PI	and	II	beta-lactams.	There	was	a	significant
reduction	in	mortality	rates	among	patients	receiving	C/PI	in	both	studies.	Roberts	et	al	2016	(41)	observed
higher	clinical	rates	and	reduced	mortality	in	C/PI	patients	and	Lal	et	al	2016	(38)	found	C/PI	to	reduce	clinical
failure	rates.
Finding	in	this	study	are	consistent	with	published	reviews	focused	specifically	on	piperacillin-tazobactam	(4,42–
44).	Yusuf	el	at	2014	(4)	reviewed	literature	comparing	the	effectiveness	of	C/PI	and	II	administration	of
piperacillin-tazobactam.	They	documented	C/PI	improved	clinical	cure,	mortality	and	length	of	hospital	stay	in
comparison	to	II.	Yang	et	al	2015/6	(43,44)	observed	similar	beneficial	effects	of	C/PI	in	their	systematic	reviews.
Recently,	Rhodes	et	al	2017	(42)	evaluated	a	wide	range	of	severely	ill	patients,	from	hospitalised	patients	to
critically	ill	patients	admitted	to	ICU.	C/PI	piperacillin-tazobactam	is	associated	with	improved	clinical	outcome
and	significantly	reduced	mortality	rates.
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Several	limitations	of	this	analysis	should	be	noted.	First,	clinical	heterogeneity	was	present	as	selected	studies
comparing	C/PI	and	II	in	terms	of	clinical	outcomes	have	confounding	factors	including	patient	sample	size,	study
settings,	study	design,	quality,	intervention	and	outcomes.	The	benefits	and	outcome	gain	achieved	with	C/PI
administration	in	comparison	to	II	is	difficult	to	quantify	as	studies	selected	show	considerable	heterogeneity	in
terms	of:	(1)	type	of	isolated	bacteria,	(2)	piperacillin-tazobactam	dose,	(3)	MIC	of	pathogen,	(4)	patient	renal
function,	(5)	duration	of	hospital	stay	and	(6)	outcome	definitions.	Second,	information	regarding	monotherapy
and	combination	antibiotic	therapy	were	not	reported	in	the	included	studies.	This	reduces	the	validity	of
conclusions	on	C/PI,	as	agents	used	possess	different	antimicrobial	spectrum,	and	drug-drug	interactions	were
unknown	hence	not	considered.	Third,	assessing	safety	was	challenging	due	to	under-reporting	of	adverse
events.	Higher	serum	concentrations	in	C/PI	patients	over	a	longer	period	could	potentially	result	in	an	increased
number	of	adverse	events.	Fourth,	throughout	this	review,	PI	and	CI	were	combined	and	referred	to	as	C/PI,	thus,
it	is	unclear	which	of	the	two	dosing	strategies	is	most	effective	for	critically	ill	patients.	Fifth,	a	large	number	of
included	studies	were	RCT’s	(10/23;	43.5%)	with	small	sample	size.	Small	sample	size	may	result	in	bias	and	the
probability	of	small	study	effects	contributing	to	the	favourable	outcome	for	C/PI.	However,	meta-analyses
including	small	and	large	studies	did	not	indicate	significant	discrepancies	and	similar	outcomes	were	observed
with	fixed	and	random	effect	models.
5	Conclusion
In	conclusion,	C/PI	of	piperacillin-tazobactam	in	critically	ill	patients	was	associated	with	(1)	higher	clinical	cure
rates	(2)	lower	of	mortality	rates,	(3)	higher	microbiological	success	rates	and,	(4)	a	reduction	in	adverse	events
and	(5)	decreasing	the	length	of	hospital	stay	in	critically	ill	ICU	patients.	There	is	a	significant	level	of	evidence
that	clinical	outcome	in	critically	ill	patients	is	better	in	those	receiving	C/PI.	Therefore,	this	alternative	infusion
strategy	could	be	recommended	in	clinical	practice.
Abbreviations
C.I
Confidence	Interval
CI
Continuous	Infusion
C/PI
Continuous/Prolonged	Infusion
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ICU
Intensive	Care	Unit
II
Intermittent	Infusion
MD
Mean	Difference
MIC
Minimal	Inhibitory	Concentration
OR
Odds	Ratio
PD
Pharmacodynamics
PI
Prolonged	Infusion
PK
Pharmacokinetics
RCT
Randomised	Controlled	Trials
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Figure	1
Flow	diagram	illustrating	the	selection	process	for	included	studies
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Figure	2
Forest	plot	representing	the	odds	ratio	of	clinically	cured	patients	from	the	C/PI	and	II	patients	in
included	studies
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Figure	3
Symmetric	funnel	plot	indicating	the	absence	of	publication	bias	in	terms	of	clinical	cure
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Figure	4
Forest	plot	representing	the	odds	ratio	of	mortality	patients	from	C/PI	and	II	patients	in	included	studies
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Figure	5
Symmetric	funnel	plot	indicating	the	absence	of	publication	bias	in	terms	of	patient	mortality
Figure	6
Forest	plot	representing	the	odds	ratio	of	microbiologically	cured	patients	from	the	C/PI	and	II	patients
in	included	studies
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Figure	7
Symmetric	funnel	plot	indicating	the	absence	of	publication	bias	in	terms	of	microbiological	cure
Figure	8
Forest	plot	representing	the	odds	ratio	of	adverse	events	experienced	by	patients	from	the	C/PI	and	II
groups	in	included	studies
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Figure	9
Forest	plot	representing	the	MD	of	length	of	hospital	stay	in	C/PI	and	II	groups	in	included	studies
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Figure	10
a)	Risk	of	bias	summary	of	included	RCT’s:	displaying	details	about	each	risk	of	bias	item	for	each	trial.
Green	(+)	indicates	‘low	risk’,	red	(-)	indicates	‘high	risk’	and	yellow	(?)	indicates	‘unclear	risk’.	b)	Risk
of	bias	assessment	displaying	judgements	about	each	risk	of	bias	item	presented	as	percentages	across
all	RCT’s
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